Skip to main content
OpenTrials
Completed

NCT Number: NCT02599688

Open Label Extension of LipoLat-CS202

This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Professional Research Network

Goose Creek, South Carolina, 29445, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Inclusion criteria
  • Successful completion of 3 months of participation in Study LipoLat-CS202.
  • Treatment with POLAT-001 in Study LipoLat-CS202.
  • Able and willing to give signed informed consent and follow study instructions.
  • Exclusion criteria

Excluded from the study will be individuals with the following characteristics:

  • The development, during study LipoLat-CS202, of any exclusion criteria from that study (e.g., concomitant medication or co-morbid disease).

Treatment and study plan

observation only

Other

No intervention in this study.

Primary outcomes

  1. Intraocular Pressure (IOP)

    Time frame: 3 months

    Mean change from baseline (Visit 1 in Study LipoLat-CS202, NCT02466399) IOP at Month 3 (6 months after treatment in LipoLat-CS202).

Sponsors and collaborators

Lead sponsor

Peregrine Ophthalmic

Industry

Registry information

Official study title

An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Nov 6, 2015
Registry last updated
Dec 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.